

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1-7. Canceled.

8. (Currently amended) A compound having the following general formula
(VII)

(VI)-Y-R₁₀

wherein (VI) is the general formula: (VI) according to claim 6



wherein R_a is a phenyl group; a substituted phenyl group having one or more substituents wherein the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C₁₋₄alkylamino, C₁₋₄dialkylamino, halogen, perfluoro C₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; a benzyl group; a substituted benzyl group with one or more substituents where the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C₁₋₄alkylamino, C₁₋₄dialkylamino, halogen, perfluoro C₁₋₄alkyl, C₁₋₃alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group; or a bicyclic aryl group having 8 to 11 ring members, which may have 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur;

R_b is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and aryl ring in the compound

may have one or more substituents selected from a group consisting of halide, hydroxy, cyano, lower alkyl, and lower alkoxy groups;

R_c is a saturated or unsaturated C₁₋₆alkyl, C₁₋₆alkoxy, perfluoro C₁₋₆alkyl group; and

X₁, X₂, and X₃ may be the same or different and independently selected from hydrogen, hydroxyl, and halide;

Y is oxygen, sulfur, or nitrogen of a group selected from R_a, R_b, R_c, X₁, X₂ and X₃;

R₁₀ is phosphate, hemisuccinate, phosphoryloxymethyloxycarbonyl, dimethylaminoacetate, amino acid, or a salt thereof; and

the compound having general formula (VII) is capable of serving as a substrate for a phosphatase or a carboxylase and is thereby converted to a compound having general formula (VI).

9-11. Canceled.

12. (Currently amended) A pharmaceutical composition comprising a compound according to any one of claims 1-8 and a pharmaceutically acceptable carrier.

13. (Currently amended) ~~A~~The pharmaceutical composition of claim 12, the composition comprising a safe and effective amount of the compound.

14-15. Canceled.

16. (Currently amended) A method for carrying out a binding assay, comprising:

a) providing a composition comprising a first co-activator and an interacting protein, said first co-activator comprising a binding motif of LXXLL, LXXLI or FXXFF wherein X is any amino acid;

b) combining the first co-activator and the interacting protein with a test compound; and

c) detecting alteration in binding between the first co-activator and the interacting protein in the presence of the compound;
wherein the test compound is selected from a compound of ~~any one of~~ claims 1-8.

17. (Original) The method of claim 16, wherein said interacting protein is a transcription factor or a second co-activator.

18. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of RIP140; SRC-1 (NCoA-1); TIF2 (GRIP-1; SRC-2); p (CIP; RAC3; ACTR; AIB-1; TRAM-1; SRC-3); CBP (p300); TRAPs (DRIPs); PGC-1; CARM-1; PRIP (ASC-2; AIB3; RAP250; NRC); GT-198; and SHARP (CoAA; p68; p72).

19. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of TAL 1; p73; MDm2; TBP; HIF-1; Ets-1; RXR; p65; AP-1; Pit-1; HNF-4; Stat2; HPV E2; BRCA1; p45 (NF-E2); c-Jun; c-myb; Tax; Sap 1; YY1; SREBP; ATF-1; ATF-4; Cubitus; Interruptus; Gli3; MRF; AFT-2; JMY; dMad; PyLT; HPV E6; CITTA; Tat; SF-1; E2F; junB; RNA helicase A; C/EBP β ; GATA-1; Neuro D; Microphthalmia; E1A; TFIIB; p53; P/CAF; Twist; Myo D; pp90 RSK; c-Fos; and SV40 Large T.

20. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of ERAP140; RIP140; RIP160; Trip1; SWI1 (SNF); ARA70; RAP46; TIF1; TIF2; GRIP1; and TRAP.

21. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of VP16; VP64; p300; CBP; PCAF; SRC1 PvALF; AtHD2A; ERF-2; OsGAI; HALF-1; C1; AP-1; ARF-5; ARF-6; ARF-7; ARF-8; CPRF1; CPRF4; MYC-RP/GP; and TRAB1.

22. (Original) The method of claim 16, wherein said first co-activator is CBP or p300.

23. (Currently amended) A method for inhibiting tumor growth comprising administering to a mammalian subject having a tumor a compound according to ~~any one of~~ claims 1-8, ~~or a composition according to claim 12 or claim 13,~~ in an amount effective to inhibit the growth of the tumor in the mammalian subject.

24. (Original) The method of claim 23 wherein the tumor is cancerous.

25. (Original) The method of claim 23 wherein the tumor is colorectal cancer.

26. (Currently amended) A method of treating or preventing cancer comprising administering to a subject in need thereof a compound according to ~~any one of~~ claims 1-8, ~~or a composition according to claim 12 or claim 13,~~ in an amount effective to treat or prevent the cancer.

27. (Original) The method of claim 26 wherein the cancer is colorectal cancer.

28. (Original) The method of claim 26 wherein the compound or the composition is administered in combination with an anti-neoplastic agent.

29. (Original) The method of claim 28 wherein the anti-neoplastic agent is selected from the group consisting of 5-FU, taxol, cisplatin, mitomycin C, tegafur, raltitrexed, capecitabine, and irinotecan.

30. (Currently amended) A method of treating or preventing restenosis associated with angioplasty comprising administering to a subject in need thereof an amount of a compound according to ~~any one of~~ claims 1-8, ~~or a composition according to claim 12 or claim 13,~~ where the amount is effective to prevent the restenosis.

31. (Currently amended) A method of treating or preventing polycystic kidney disease comprising administering to a subject in need thereof an amount of a compound according to ~~any one of claims 1-8, or a composition according to claims 12 or 13~~, where the amount is effective to treat the polycystic kidney disease.

32. (Currently amended) A method of treating or preventing aberrant angiogenesis disease comprising administering to a subject in need thereof an amount of a compound according to ~~any one of claims 1-8, or a composition according to claim 12 or claim 13~~, where the amount is effective to treat the aberrant angiogenesis disease.

33. (Currently amended) A method of treating or preventing rheumatoid arthritis disease comprising administering to a subject in need thereof an amount of a compound according to ~~any one of claims 1-8, or a composition according to claim 12 or claim 13~~, where the amount is effective to treat the rheumatoid arthritis disease.

34. (Currently amended) A method of treating or preventing ulcerative colitis comprising administering to a subject in need thereof an amount of a compound according to ~~any one of claims 1-8, or a composition according to claim 12 or claim 13~~, where the amount is effective to treat the ulcerative colitis.

35. (Currently amended) A method for treating or preventing tuberous sclerosis complex (TSC) comprising administering to a subject in need thereof an amount of a compound of ~~any of claims 1-8, or a composition of claim 12 or claim 13~~, where the amount is effective to treat or prevent TSC.

36. (Currently amended) A method for treating or preventing a KSHV-associated tumor comprising administering to a subject in need thereof an amount of a compound of ~~any of claims 1-8, or a composition of claim 12 or claim 13~~, where the amount is effective to treat or prevent the KSHV-associated tumor.

37. (Currently amended) A method for modulating hair growth comprising administering to a subject in need thereof an amount of a compound of ~~any of claims 1-8, or a composition of claim 12 or claim 13~~, where the amount is effective to modulate hair growth on the subject.

38. (Currently amended) A method of treating or preventing Alzheimer's disease comprising administering to a subject in need thereof an amount of a compound according to ~~any one of claims 1-8, or a composition according to claim 12 or claim 13~~, where the amount is effective to treat or prevent Alzheimer's disease.

39. (Currently amended) A method for promoting neurite outgrowth, comprising contacting a neuron with a compound according to ~~any one of claims 1-8, or a composition according to claim 12 or claim 13~~, in an amount effective to promote neurite outgrowth.

40. (Currently amended) A method for promoting differentiation of a neural stem cell comprising contacting a neural stem cell with a compound according to ~~any one of claims 1-8, or a composition according to claim 12 or claim 13~~, where the amount is effective to promote differentiation of the neural stem cell.

41. (Currently amended) A method for promoting apoptosis in cancer cells comprising contacting cancer cells with a compound according to ~~any one of claims 1-8, or a composition according to claim 12 or claim 13~~, in an amount effective to promote apoptosis in the cancer cells.

42. (Currently amended) A method for inhibiting survivin expression in a cell comprising contacting a survivin-expressing cell with a compound according to ~~any one of claims 1-8, or a composition according to claim 12 or claim 13~~, in an amount effective to inhibit survivin expression.

43. (New) The compound of claim 8, wherein

R_a is a phenyl group; a substituted phenyl group having one or more substituents wherein the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4} alkylamino, C_{1-4} dialkylamino, halogen, perfluoro C_{1-4} alkyl, C_{1-4} alkyl, C_{1-3} alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; a benzyl group; a substituted benzyl group with one or more substituents where the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4} alkylamino, C_{1-4} dialkylamino, halogen, perfluoro C_{1-4} alkyl, C_{1-3} alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group; a naphthyl group; a quinolinyl group; an indazolyl group; or a benzpyrazolyl group; an isoquinolinyl group; and

R_b is phenyl, pyridyl or piperidyl, all of which may be substituted with one or more substituents selected from a group consisting of halide, hydroxy, cyano, lower alkyl, and lower alkoxy groups.

Amendments to the Drawings:

The attached sheet of drawings includes changes to Figure 17. This sheet, Figure 17, replaces the original sheet including Figure 17.

Attachment: Replacement Sheet, Figure 17.